News
![astrazeneca-sign](https://pharmaphorum.com/wp-content/uploads/2017/08/AstraZeneca-sign.jpg)
AZ, MSD's Koselugo is first EU therapy for neurofibromatosis
The European Commission has approved AstraZeneca and MSD's Koselugo for a rare genetic condition that causes tumours to develop on the covering of nerve cells, leading to disfigurement and